IN THE NEWS: Key Updates in Non-Metastatic and Metastatic Prostate Cancer Treatment

OncLive

Elisabeth Heath, M.D., FACP, medical oncologist, leader of the Genitourinary Oncology Multidisciplinary Team (MDT), member of the Phase 1 Clinical Trials MDT, and associate director of Translational Sciences at Karmanos, joins a panel of prostate cancer experts discussing new data on the treatment and management of nmCRPC, mHSPC, and mCRPC. Key Updates in Non-Metastatic and Metastatic Prostate Cancer Treatment covers multiple topics in the following episodes:

1. Breakthroughs in imaging modalities for prostate cancer
2. Prostate cancer imaging: Unmet needs and knowledge gaps
3. Recent progress in the prostate cancer treatment landscape
4. Key unmet needs in prostate cancer management
5. Goals of treatment for non-metastatic castration-resistant prostate cancer
6. nmCRPC: Clinical trial data on AR inhibitors
7. AR inhibitors in nmCRPC: Real-world data
8. Importance of quality of life when choosing therapy for nmCRPC
9. Non-metastatic castration-resistant prostate cancer: Patient monitoring strategies
10. Optimizing care for patients with non-metastatic CRPC
11. Treatment goals for patients with metastatic hormone-sensitive prostate cancer
12. Factors in selecting therapy for patients with metastatic hormone-sensitive prostate cancer
    
13. mHSPC: Use of triplet therapy
14. Metastatic hormone-sensitive prostate cancer: Data from ARASENS and ARANOTE
15. Metastatic hormone-sensitive prostate cancer: Data from ENZAMET and ARCHES
16. Metastatic hormone-sensitive prostate cancer: Data from TITAN and PEACE-1
17. Educating patients on treatment options in metastatic HSPC
18. Novel treatment modalities in metastatic hormone-sensitive prostate cancer
19. Overview of the metastatic castration-resistant prostate cancer treatment paradigm
20. Metastatic CRPC: Advent of PARP inhibitors
21. Practical application of PARP inhibitors in metastatic CRPC
22. IO therapy in mCRPC and clinical pearls

Watch all episodes here.